Pacer Advisors Inc. Has $258.37 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Pacer Advisors Inc. significantly increased its stake in Regeneron Pharmaceuticals by 2,296.9%, owning 407,370 shares worth approximately $258.36 million as of the most recent filing.
• Multiple hedge funds have also raised their positions in Regeneron, with Capital International Investors boosting its stake by 41.6% in the fourth quarter.
• Regeneron Pharmaceuticals recently reported a quarterly revenue of $3.03 billion, missing estimates, alongside an earnings per share of $8.22, which was below analyst expectations.

Pacer Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2,296.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 407,370 shares of the biopharmaceutical company's stock after buying an additional 390,374 shares during the period. Pacer Advisors Inc. owned about 0.37% of Regeneron Pharmaceuticals worth $258,366,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on REGN. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Bank of America cut their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Stock Down 1.4%

Regeneron Pharmaceuticals stock opened at $564.64 on Friday. The firm has a market cap of $60.96 billion, a price-to-earnings ratio of 14.37, a PEG ratio of 2.14 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a 50 day moving average price of $543.18 and a two-hundred day moving average price of $610.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the business earned $9.55 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.